Despite improving success rate of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) lesions, the clinical benefit of recanalization of CTO is still a matter of debates. The purpose of this study is to elucidate the impact of successful PCI for CTO on cardiovascular outcome in a large Japanese observational database of patients who underwent first coronary revascularization. Among 13087 patients who underwent PCI in the CREDO-Kyoto registry Cohort-2, 1524 patients received PCI for CTO. Clinical outcomes were compared between 1192 patients with successful CTO-PCI and 332 patients with failed CTO-PCI. In-hospital death tended to occur less frequently in the successful CTO-PCI group than in the failed CTO-PCI group (1.4% vs. 3.0%, P=0.053). Through 3-year follow-up, the cumulative incidence of all-cause death was not significantly different between the successful and failed CTO-PCI groups (9.0% vs. 13.1%, p=0.18), while the cumulative incidence of cardiac death was significantly lower in the successful CTO-PCI group than in the failed CTO-PCI group (4.5% CTO-PCI has been reported to be associated with less subsequent coronary artery bypass grafting (CABG), improvement of left ventricular function and relief of symptoms. [4] [5] [6] There are several reports that successful CTO-PCI improved the long-term survival outcomes after revascularization. [7][8] Recently, Mehran and Jones also reported successful PCI for CTO was independently associated with lower cardiac morality. 9-10 However, many previous studies were associated with relatively low procedural success rates. Procedural success rate itself might have significant influence in analyzing the effect of successful CTO-PCI on survival outcome. Survival outcome after CTO-PCI should also be investigated in a population with relatively high procedural success rates. Therefore, we analyzed the impact of successful PCI for CTO on cardiovascular outcomes in a large Japanese observational database of patients who underwent first coronary revascularization.
informed consents from the patients were waived; however, we excluded those patients who refused participation in the study when contacted for follow-up. This strategy is concordant with the guidelines for epidemiological studies issued by the Ministry of Health, Labor and Welfare of Japan.
The design and patient enrollment of the CREDO-Kyoto PCI/CABG registry cohort-2 has been described previously.
11 Among a total of 15263 patients, 13087 patients underwent PCI as their first coronary revascularization procedure during the 3 years of enrollment period. Among 2491 patients (19%) with at least 1 CTO lesion, 1524 patients underwent attempt of PCI for CTO lesions. PCI for at least one CTO lesion was successful in 1192 patients (successful CTO-PCI group), while PCI for CTO lesions was unsuccessful in 332 patients (failed CTO-PCI group) (78% initial patient success rate for CTO) ( Figure 1 ). The number of cases and initial success rate of CTO-PCI in each participating center were illustrated in Supplemental Figure 1 . In the successful PCI group, 1230 lesions out of 1245 CTO lesions in 1192 patients were successfully treated (1154 patients had 1 treated CTO lesion and 38 patients had 2 treated CTO lesions). A total of 2032 stents were used in the successful CTO-PCI group; 1589 were drug-eluting stents (78%) and 443 were bare-metal stents (22%). In the failed PCI group, no CTO lesion among 339 CTO lesions in 332 patients was successfully treated, while 262 non-CTO lesions were successfully treated in 177 patients. In the current pre-specified substudy of the Demographic, angiographic, and procedural data were collected from hospital charts or databases according to the pre-specified definitions by the experienced clinical research coordinators in the independent clinical research organization (Research Institute for Categorical variables were compared with the chi-square test. Continuous variables were expressed as mean value ± standard deviation or median and IQR. Continuous variables were compared using the Student's t-test or Wilcoxon rank sum test based on their distributions. Cumulative incidence was estimated by the Kaplan-Meier method and differences were assessed with the log-rank test. We used Cox proportional hazard models to estimate the risk of the successful CTO-PCI group relative to the failed CTO-PCI group adjusting for the differences in patient characteristics and procedural factors as well as medications. In consistent with our previous reports, we selected 34 clinically relevant factors shown in Table 1 as potential independent risk-adjusting variables.
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Independent correlates for all-cause death were identified by a backward elimination procedure (Supplemental Table 1 ). The final model incorporated the successful CTO-PCI together with 8 variables remaining after the backward procedure. Adjusted analysis for the other endpoints was performed by using the same 8 risk-adjusting variables as used in the analysis for all-cause death. The continuous variables were dichotomized by clinically meaningful reference values or median values. The effect of the successful CTO-PCI (the successful CTO-PCI group compared to the failed CTO-PCI group) was expressed as hazard ratios (HR) and their 95% confidence intervals (CI). Post-hoc subgroup analysis was also conducted for an exploratory purpose in several clinically relevant subgroups. Statistical analyses were conducted by two physicians (Yamamoto E and Natsuaki M) and by a statistician (Morimoto T) with the use of JMP 10.0 (SAS Institute Inc, Cary, NC) and SAS 9.2 (SAS Institute Inc, Cary, NC) softwares. All the statistical analyses were two-tailed. P values <0.05 were considered statistically significant.
Results
At baseline, acute myocardial infarction, shock at presentation, multivessel disease, moderate to severe mitral regurgitation and dialysis were more prevalent in the failed CTO-PCI group than in the successful CTO-PCI group, while prior MI was more common in the successful CTO-PCI group. Regarding lesion and procedural characteristics, right coronary artery was more frequently targeted in the failed CTO-PCI group than in the successful PCI group. Aspirin and thienopyridine were more frequently used in the successful CTO-PCI group than in the failed CTO-PCI group, while nitrates were more often used in the failed CTO-PCI group (Table 1) .
Regarding the procedural complications, coronary perforation was significantly more frequent in the failed CTO-PCI group than in the successful CTO-PCI group. However, there was no significant difference in the incidences of coronary dissection, cardiac tamponade and pericardial drainage between the 2 groups (Table 2) .
Regarding the in-hospital adverse events, incidence of death and MI tended to be lower in the successful CTO-PCI group. However, there was no significant difference in the incidence of stroke between the 2 groups ( Figure 2) . Through 3-year follow-up, the cumulative incidence of all-cause death was not significantly different between the successful and failed CTO-PCI groups, while the cumulative incidence of cardiac death was significantly lower in the successful CTO-PCI group than in the failed CTO-PCI group (Table   3 , and Figure 2 ). After adjusting confounders, however, the risks of successful PCI relative to failed PCI for both all-cause death and cardiac death were not significant (Table 3 ). There was no significant difference in the incidences of MI, stroke and definite ST between the 2 groups ( Table 3 , and Figure 3 ). The adjusted risks of successful PCI relative to failed PCI for MI, stroke and definite ST were also not significant (Table 3 ). Cumulative incidence of CABG was remarkably lower in the successful PCI group than in the failed PCI group. The cumulative incidence of any coronary revascularization was also lower in the successful PCI group than in the failed PCI group (Figure 3 ). Even after adjusting confounders, the lower risk of successful PCI relative to failed PCI for CABG and any coronary revascularization remained significant (Table 3 ).
In the post-hoc subgroup analysis, successful PCI was not associated with lower risk for all-cause death in any of the subgroups evaluated. However, successful PCI was associated with lower risk for cardiac death in several subgroups including patients with treated CTO lesion located in left anterior descending artery, patients with single vessel disease, patients without history of heart failure, and patients without diabetic mellitus (Table 4) .
Discussion
The main findings of the current study are as follows: (1) Successful PCI for CTO as compared with failed PCI for CTO was not associated with lower risk for 3-year mortality; (2) However, successful PCI for CTO was associated with significantly lower risk for subsequent CABG. CTO-PCI was one of the most challenging fields in the interventional cardiology in the past decade. In the early 2000s, the success rate of CTO-PCI was 60%-70%.
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Recently, the reported success rate of CTO-PCI has reached >80% owing to the development of devices such as tapered wires or micro-catheters as well as advances in operators' techniques such as parallel wire technique and retrograde approach. [16] [17] [18] [19] In consistent to these reports, initial patient success rate of CTO-PCI was 78% in this study. Successful CTO-PCI is reported to be associated with less subsequent CABG, improvement in left ventricular function and relief of symptoms, which are the main reasons for physicians to perform CTO-PCI. [4] [5] [6] However, the impact of successful PCI for CTO on long-term prognosis is still a matter of debates. 8,20-23 Most of previous studies evaluating the impact of successful CTO-PCI on long-term outcome adopted the methodology comparing the long-term mortality after successful CTO-PCI with that after failed CTO-PCI. Suero and Hoye reported successful revascularization of CTO were independent predictors of all-cause death. 7, 15 Recently, Mehran reported that successful PCI for CTO was an independent predictor of all-cause death and cardiac death.
successful PCI group in previous reports. Mehran et al. reported rate of coronary perforation and residual dissection was 7.4% and 9.4% respectively in failed group, and 1.7% and 4.3% in success group. 9 Olivari reported that 2.3%
of patients in the failed CTO-PCI group underwent emergent CABG (no emergent CABG in our study).
included in the successful CTO-PCI group in our study could be included in the failed CTO-PCI group in these previous reports, leading to worse survival outcome in the failed CTO-PCI group. Indeed, the failed CTO-PCI group in these previous reports included more patients with older age, 23 lower left ventricular ejection fraction, and previous MI 10 than the successful CTO-PCI group, while in the current study, there was no significant difference between the successful and failed CTO-PCI groups with regard to these factors.
There is no randomized controlled trial comparing PCI plus medical therapy with medical therapy alone in patients with CTO. Given the discrepancy between the current and previous studies in terms of long-term mortality benefit of successful CTO-PCI, it is currently unclear whether successful CTO-PCI could improve long-term mortality. Recently, the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME-2) study demonstrated that in patients with stable coronary artery disease (CAD) and functionally significant stenosis, PCI guided by fractional flow reserve plus the best available medical therapy, as compared with the best available medical therapy alone, decreased the need for urgent revascularization. 26 However, the benefit of avoiding the need for urgent revascularization could not be expected in stable CAD patients with CTO. A significant proportion of stable CAD patients with CTO are asymptomatic and therefore, we also could not expect symptomatic relief in this patient population. Furthermore, recent prospective randomized trials comparing PCI using DES with CABG in patients with complex multivessel CAD clearly demonstrated better long-term survival with less MI during follow-up with CABG. 27-28 Therefore, most of the complex multivessel CAD patients with CTO should be referred to CABG surgery, although the above mentioned randomized controlled trials included relatively small number of patients with CTO (6-24%). According to these recent observations, the appropriate indications for CTO-PCI seemed to be limited.
In the exploratory subgroup analysis of this study, successful PCI was associated with lower risk for cardiac death in several subgroups. Safley also reported that successful PCI for CTO was a multivariable predictor for long-term survival in patients with treated LAD CTO lesion. 29 Therefore, it is possible that successful CTO-PCI could be associated with improved survival outcome in some selected subgroups of patients. However, we should be very careful in interpreting the results of the subgroup analysis in the overall negative study.
Prospective randomized trials comparing PCI plus medical therapy with medical therapy alone in patients There are several limitations in this study. This is an observational study and the baseline patient characteristics were significantly different between the 2 groups. Despite statistical adjustment, it was not certain whether the mortality outcome was related to the successful CTO-PCI itself or was related to the presence of unmeasured confounders. Second, the current analysis was obviously underpowered in evaluating long-term mortality, although we enrolled relatively large number of patients with CTO as compared with previous studies.
Third, there were no criteria to perform PCI for CTO lesions and the decision was left to each attending physician.
Therefore, the conclusions of the current study could not be extrapolated to CTO-PCI in general. Fourth, patients with failed CTO-PCI are not equivalent to those patients with CTO who were managed with medical therapy alone.
Fifth, the skill for CTO-PCI is demanding and therefore, procedural outcome as well as long-term outcome could be different according to the centers or operators. Sixth, the low treatment rate of statins, beta blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers may have significant impact on the overall event rates at follow-up. Seventh, successful intervention of non-CTO lesions may lead to difficulty in detecting a difference between the 2 groups. Furthermore, high rate of subsequent coronary revascularization in patients with failed CTO-PCI might have attenuated the possible long-term mortality benefit of successful CTO-PCI in this study.
Eighth, the duration of DAPT was different between the successful and failed PCI group, which might have influenced the long-term outcome. Finally, there was no information about the viability or ischemia in the myocardial territory subtended by the targeted lesions in this study.
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Disclosures
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CTO, chronic total occlusion.
Figure 2.
Cumulative incidences of (A) all-cause death and (B) cardiac death: the success PCI vs. failed PCI group.
PCI, percutaneous coronary intervention; 
Cumulative incidences of (A) myocardial infarction, (B) stroke, (C) CABG and (D) any coronary revascularization:
the success PCI vs. failed PCI group.
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting. Values are expressed as mean ± SD or median (inter-quartile range).
BMI indicated body mass index; eGFR, estimated glomerular filtration rate; CTO, chronic total occlusion; ACE-I, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers.
* Potential independent variables selected for Cox proportional hazard models.
** Risk-adjusting variables. Cumulative incidence was estimated by the Kaplan-Meier method.
HR indicated hazard ratio; CI, confidence interval. 
